Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy

Key Points

• To evaluate the relationship between serum transthyretin levels after tafamidis treatment and survival in transthyretin amyloid cardiomyopathy.
• Evaluated serum transthyretin levels in patients receiving tafamidis.
• Analyzed survival outcomes associated with serum transthyretin increases.
• Patients with increased serum transthyretin levels after tafamidis showed improved survival rates.
• Statistical analysis indicated a significant link between higher transthyretin levels and improved prognosis.